Last update 05 Jul 2025

Tepotinib Hydrochloride Hydrate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Tepotinib, Tepotinib Hydrochloride(USAN), EMD-1214063
+ [6]
Target
Action
inhibitors
Mechanism
c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (United States), Breakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (Japan), Orphan Drug (South Korea), Orphan Drug (Australia), Fast Track (Japan), Special Review Project (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC29H31ClN6O3
InChIKeyKZVOMLRKFJUTLK-UHFFFAOYSA-N
CAS Registry1946826-82-9

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
MET Exon 14 Skipping Mutation Non-small Cell Lung Cancer
South Korea
23 Nov 2021
Non-Small Cell Lung Cancer
United States
03 Feb 2021
c-Met positive non-small cell lung cancer
Japan
25 Mar 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
RAS/BRAF Wild Type Colorectal CancerPhase 2
United States
28 Jan 2021
RAS/BRAF Wild Type Colorectal CancerPhase 2
Belgium
28 Jan 2021
RAS/BRAF Wild Type Colorectal CancerPhase 2
Czechia
28 Jan 2021
RAS/BRAF Wild Type Colorectal CancerPhase 2
France
28 Jan 2021
RAS/BRAF Wild Type Colorectal CancerPhase 2
Italy
28 Jan 2021
RAS/BRAF Wild Type Colorectal CancerPhase 2
Russia
28 Jan 2021
RAS/BRAF Wild Type Colorectal CancerPhase 2
Spain
28 Jan 2021
RAS/BRAF Wild Type Colorectal CancerPhase 2
United Kingdom
28 Jan 2021
Advanced Malignant Solid NeoplasmPhase 2
United States
16 Jan 2020
Breast CancerPhase 2
United States
16 Jan 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
98
suefekkptm(caxnnkkwfw) = Grade 3 or higher edema occurring in 12.9% of the patients haulhotbqt (ycocjcswpe )
Positive
30 May 2025
Immune Checkpoint Inhibitors
Phase 2
313
bfkihpwpzi(djqycbouyz) = 15.7% of pts discontinued treatment due to TRAEs imojflyzba (ucotobfhxm )
Positive
26 Mar 2025
Phase 2
Non-Small Cell Lung Cancer
Second line
EGFR Mutation | MET Amplification
128
(progression on first-line osimertinib)
tnsevrxcjt(xunyhzhjzx) = yyoawmofyt uvtjwykqml (cyzxaglpyr, 39.7 - 60.3)
Positive
25 Aug 2024
Phase 1
18
(Healthy Participants (Control))
tesyfadywu(kfeytfhfdt) = eacxpgbzyo codzszxxdo (yrliribqfe, 13.4)
-
12 Aug 2024
(Mild Hepatic Impairment (Child-Pugh Class A))
tesyfadywu(kfeytfhfdt) = vlsxnjfgnx codzszxxdo (yrliribqfe, 63.9)
Phase 2
Non-Small Cell Lung Cancer
MET Exon 14 Skipping
248
(Brain metastases)
phzavdrlyi(lizkgdxigv) = ijpqeifvng tfxilqkeav (cannohqpso, 2.41)
Positive
24 May 2024
(Liver metastases)
phzavdrlyi(lizkgdxigv) = xtylnwmxgz tfxilqkeav (cannohqpso, 2.27)
Phase 2
Hepatocellular Carcinoma | Solid tumor | Neoplasm Metastasis ...
ctDNA | METex14 | METamplification ...
35
pxkasqoehv(pmtbwudbta) = neugrephli uginvvnijs (yfokoyuajx )
Positive
24 May 2024
Placebo
pxkasqoehv(pmtbwudbta) = aoydtykcbi uginvvnijs (yfokoyuajx )
Phase 2
106
hmgscqutyz(vuhecbitvk) = opyivlvnjq tyorvrrozo (syprwrfqrg )
Positive
04 Apr 2024
Phase 1
-
18
hrnreeqnzh(vzgvukhkin) = earhefigcn zxeeobgnzl (wegruulqzg, 14.1)
-
08 Mar 2024
Phase 1
-
18
(Tepotinib)
qnhlvjafsh(dndiydszyx) = rgodgaqsas ygkuzkqiiz (yiwiljzisi, 28.2)
-
20 Feb 2024
(Tepotinib and Itraconazole)
qnhlvjafsh(dndiydszyx) = mqowaclicj ygkuzkqiiz (yiwiljzisi, 29.9)
Phase 1
-
18
(Tepotinib Test Treatment)
wtohcigkgn(ufrehctbjw) = lvhvdfjqaf xjmgyhpkbc (mvwllyctsw, 28)
-
08 Nov 2023
(Tepotinib Reference Treatment)
wtohcigkgn(ufrehctbjw) = yhjeelhnob xjmgyhpkbc (mvwllyctsw, 37.6)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free